Astma, aspirine en kanker.*
Uit twee grote studies wordt meer en meer duidelijk dat het verminderen van ontstekingen leidt tot minder kans op het ontstaan van kanker. In de ene studie bleek dat de ontstekingsremmer aspirine de kans op het krijgen van kanker met 16% doet dalen. In de andere studie, die eerst uitgevoerd werd met muizen en nadien bevestigd werd in vrouwen met borstkanker, bleek dat astma bij vrouwen zorgde voor een duidelijk verhoogde kans op uitzaaiingen in de longen als zij longkanker krijgen of al hebben.
Of
Asthma And Aspirin: 2 Studies Highlight Role Of Inflammation In Cancer Can
reducing inflammation keep cancer at bay? Two novel studies presented at the
2007 Annual Meeting of the American Association for Cancer Research that examine
use of common anti-inflammatory agents suggest this might be the case. One large
study found that women who regularly use aspirin developed fewer cancers than
women who did not, while another, conducted in mice and now being confirmed in
an analysis of breast cancer patient records, discovered a link between asthma
and an increased risk of cancer metastasis to the lungs.
Both studies offer hope that managing inflammation can help control cancer.
Association of aspirin and non-aspirin NSAIDs with cancer incidence and
mortality in a large prospective cohort study: Abstract 3400
Regular aspirin use was associated with lower cancer incidence and cancer
mortality, but non-aspirin non-steroidal anti-inflammatory drug (NSAID) use was
not, according to one of the largest studies ever conducted to look at the
impact of these agents on overall cancer risk. Aspirin was also associated with
a lower risk of dying from coronary heart disease, while NSAIDs were not.
Among 22,507 cancer-free postmenopausal women who participated in the Iowa
Women's Health Study and provided information on aspirin and NSAID use, those
who said they regularly used aspirin had a 16 percent reduced risk of developing
cancer more than a decade later, as well as a 13 percent reduced risk of dying
from cancer over this same time period, compared to women who did not use
aspirin. But there was no statistically significant impact on cancer incidence
or mortality among women who used non-aspirin NSAIDs, compared to those who did
not, say researchers from the Mayo Clinic, in Rochester, Minnesota.
The researchers also looked at whether smoking status had any impact on the
potential preventive effects of aspirin and found that while these agents were
associated with lower cancer incidence and mortality among former and never
smokers, the same apparent benefits were not seen among active smokers.
These study results do not mean, however, that women should throw away their
NSAIDs or pick up a bottle of aspirin, says the study's lead author, Aditya
Bardia, M.D., M.P.H. "This is just one study," he says. "However,
it does provide provocative evidence that regular aspirin use may play a role in
preventing the most common chronic diseases in western countries, namely cancer
and heart disease."
The different impact of aspirin compared to other NSAIDs was somewhat surprising,
the researchers say. "While chemically different, these agents share at
least one similar mechanism of action so you might have expected them to have
comparable effects," says Jon Ebbert, M.D., the senior author on the study.
Specifically, aspirin and other NSAIDs reduce inflammation through inhibition of
cyclooxygenase (COX) enzymes. These enzymes are responsible for the formation of
prostaglandins, which can drive inflammation and possibly stimulate cancer
development in a number of organ sites, Dr. Ebbert said.
Previous studies have evaluated whether aspirin or other NSAIDs prevent specific
cancers, such as breast cancer. "But this study is unique because we were
able to evaluate comprehensive endpoints such as total cancer incidence and
cancer mortality, which are more clinically relevant outcomes for patients,"
Dr. Bardia said.
While the researchers note that one of the weaknesses of this study was that the
women were given only a single survey of aspirin and non-aspirin NSAID use, it
also had many strengths including the prospective cohort study design,
relatively long follow-up (up to 12 years) on a large number of participants,
during which time many developed (3,487) and died (1,193) from cancer. The
authors were also able to adjust the results for a large number of lifestyle
factors, and found little evidence that these other factors could explain the
aspirin and cancer associations observed in this study.
Chronic allergen provocation results in a significant increase in the rates of
lung metastasis that is dependent on induced pulmonary inflammation: Abstract
2553
An intriguing study, conducted in mice and supported by an ongoing examination
of breast cancer patient records, suggests a link between the pulmonary
inflammation seen in asthma and increased risk of lung metastasis.
The study, conducted by researchers at Mayo Clinic Arizona, suggests that breast
cancer patients who have asthma could reduce their risk of cancer spread by
using readily available inhaler medications.
"A link between pulmonary inflammation and lung metastasis would not only
have significant effects on patient diagnosis and care, but will also
immediately affect the way breast cancer patients are treated," said Anna
Taranova, M.D., a senior research fellow in the laboratory of James Lee, Ph.D.
at Mayo. "Those with asthma might be able to reduce their risk of lung
metastasis, and increase their survival, with aggressive corticosteroid
treatment."
Furthermore, the findings could prove to be relevant to asthma patients
diagnosed with other cancers that metastasize to the lungs, according to Dr.
Taranova.
"We suspect that the relationship between lung inflammation and metastasis
will not be limited to breast cancer patients," Dr. Taranova said.
The researchers say these results, along with findings from their other recent
research, offer a biological link: activation of cells that line blood vessels
is required both for the movement of pro-inflammatory white blood cells into
lung tissue (as occurs in asthma) and for the movement of circulating cancer
cells from the blood into lung tissue.
In this study, mice were exposed to an aerosolized allergen commonly used in
mouse asthma studies and then were injected with melanoma cells. Three other
groups of mice were also studied: control mice; mice that received the human
corticosteroid allergy and asthma therapeutic agent budesonide after exposure to
the allergen; and mice treated with an antibody to eliminate CD4+ T cells before
exposure to allergen. (CD4+ T cells orchestrate immune responses to allergens
and are largely responsible for the lung inflammation that occurs in asthma.)
Metastasis was continually assessed in all groups.
The researchers found that allergen-induced pulmonary inflammation was
associated with an almost 400 percent increase in lung metastasis in the mice.
But in mice treated with either an antibody to deplete CD4+ T-cells or
budesonide to reduce their allergic lung inflammation, the rate of metastasis
fell to that seen in mice that were not exposed to allergen. "The
treatments wiped out the increases in the rate of metastasis induced by allergic
inflammation, reducing the observed rates of metastasis to those found in mice
that never experienced the allergen," Dr. Taranova said.
The researchers are now working with epidemiologists at Mayo Clinic Rochester to
determine if breast cancer patients with lung metastasis had higher than normal
rates of asthma. To date, they have found "productive and provocative
results," Dr. Taranova says: over 20 percent of women with breast cancer
who developed lung metastasis also appear to have had a previous diagnosis of
asthma. The typical frequency of asthma occurrence in U.S. women is, at most,
eight percent, she said.
"Our long term goal is to continue this detailed retrospective study of
breast cancer patients, eventually translating these studies into a multi-center
prospective examination of cancer patients," Dr. Taranova said. "We
want to define the specific parameters that link lung metastasis and pulmonary
disease."
The researchers say that many questions need to be answered, including whether
asthmatics who regularly use anti-inflammatory corticosteroids experience a side
benefit of reduced risk for lung metastasis, and whether people who have
allergies, but not asthma, are at the same risk.
Dr. Taranova believes these findings are surprising, as the researchers
originally suspected that patients with asthma would have limited lung
metastasis. "However, as in most things in science, we have learned much
more from studies disproving our flawed hypotheses than from studies confirming
our preconceived ideas," she said.
###
The mission of the American Association for Cancer Research is to prevent and
cure cancer. Founded in 1907, AACR is the world's oldest and largest
professional organization dedicated to advancing cancer research. The membership
includes more than 25,000 basic, translational, and clinical researchers; health
care professionals; and cancer survivors and advocates in the United States and
more than 70 other countries. AACR marshals the full spectrum of expertise from
the cancer community to accelerate progress in the prevention, diagnosis and
treatment of cancer through high-quality scientific and educational programs. It
funds innovative, meritorious research grants. The AACR Annual Meeting attracts
over 17,000 participants who share the latest discoveries and developments in
the field. Special Conferences throughout the year present novel data across a
wide variety of topics in cancer research, diagnosis and treatment. AACR
publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer
Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer
Epidemiology, Biomarkers & Prevention. Its most recent publication, CR,
is a magazine for cancer survivors, patient advocates, their families,
physicians, and scientists. It provides a forum for sharing essential,
evidence-based information and perspectives on progress in cancer research,
survivorship and advocacy. (Mei 2007)